19,220 Shares in IQVIA Holdings Inc. $IQV Purchased by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 19,220 shares of the medical research company’s stock, valued at approximately $3,714,000.

A number of other large investors also recently made changes to their positions in the business. International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the fourth quarter worth approximately $27,000. Compass Financial Management LLC purchased a new position in IQVIA during the second quarter valued at approximately $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA in the 4th quarter valued at approximately $27,000. CrossGen Wealth LLC purchased a new stake in IQVIA in the 4th quarter worth approximately $28,000. Finally, Activest Wealth Management lifted its position in IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after buying an additional 118 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Activity

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. The trade was a 57.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,913 shares of company stock valued at $3,098,793 in the last quarter. 1.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

IQV has been the topic of several research analyst reports. Barclays restated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Royal Bank Of Canada lifted their price objective on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Stifel Nicolaus boosted their target price on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Finally, BMO Capital Markets raised their price target on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Stock Up 1.6%

IQV opened at $260.17 on Friday. The firm has a market cap of $42.82 billion, a P/E ratio of 32.28, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The business has a 50 day moving average price of $213.32 and a 200 day moving average price of $187.52. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $260.40.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter last year, the company posted $2.81 earnings per share. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has authorized a stock repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.